Gastrointestinal Cancers

Keytruda (pembrolizumab) was granted FDA approval for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received two or more lines of chemotherapy and are PD-L1-positive.

Patients with advanced gastric cancer tend to use their health care resources more often and have a worse quality of life than those without the disease

More personalized approaches are being developed to treat patients with metastatic disease.

Keytruda (pembrolizumab) showed promising signs of clinical activity for patients with advanced gastric or gastroesophageal junction (GEJ), according to updated findings from KEYNOTE-059 study that were presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.

Keytruda (pembrolizumab) was granted a priority review to a supplemental biologics license application for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have undergone at least two courses of chemotherapy.

Despite impressive efficacy for the human papillomavirus (HPV) vaccine reducing the prevalence of high-risk oral HPV infections by 88 percent, many young adults still are not getting the vaccine – sparking concern in the health community.

Although rates of the rare, but deadly disease have been declining in men since 1973, that is not the case for women.

The PD-1 inhibitor, Opdivo, may be a promising option for patients with advanced anal cancer, according to a recent study.

Dr. Daniel H. Ahn, D.O., spoke with CURE about new advances in gastroesophageal cancers including immunotherapies and stemness inhibitors.

From stigma to convenience, there are many reasons why people do not get the HPV vaccine, although it can prevent some types of cancer. Lois Ramondetta, M.D., discusses updated recommendations and hopes for getting more young people vaccinated.

Surgical palliation improved quality of live and solid food intake in patients with certain types of gastric cancer, according to a recent study.

A recent study found that Opdivo improves survival in patients with gastric or gastroesophageal junction (GEJ) cancer.

The JAVELIN trial showed that many patients with gastric cancer could benefit from immunotherapy.

Opdivo may be a promising treatment option for patients with squamous cell carcinoma of the anal canal.

Since chemotherapy can offer only a limited amount of help in fighting gastroesophageal cancers, a growing emphasis on prevention — as well as on the development of immunotherapies — will be extremely important.

For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.

In the oncology world, gastrointestinal cancers may be the next in line to realize the promise of immunotherapy.

Diagnoses in younger people and two causative infections are providing clues about how to better prevent and treat gastric cancer.

The decision to remove one's stomach may be difficult, but it can also be life-saving.

Results from new clinical trials signal a role for the immunotherapy Opdivo in the treatment of gastric cancer and heavily pretreated esophageal cancer.

I will be out on the street in New York City on November 1 to cheer on James Blake.

Moving back into the light.

The medical team had reached some conclusions.

This is how I became hospital property.